KUALA LUMPUR, March 18 (Bernama) -- AstraZeneca has made its rare disease treatment Soliris available in Malaysia, marking a significant advancement in treatment options for patients with rare ...

Complement Factor H (CFH) is a pivotal regulator of the complement system, integral to maintaining immune homeostasis and protecting host tissues from undue complement‐mediated damage. By inhibiting ...

Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...

RGC-32, or Response Gene to Complement 32, plays a pivotal role in mediating cellular responses following complement activation. Acting as a regulator of the cell cycle, RGC-32 is implicated in ...

A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare and progressive kidney diseases that often lead to kidney failure. Both involve overactivity in ...

Researchers have developed a diagnostic chip that analyzes leukocyte adhesion to detect cancer recurrence and evaluate chemotherapy effectiveness.

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.